Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor, Pomalidomide, and Dexamethasone for CNS-involved Multiple Myeloma
NCT05478993Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Oct 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in multiple myeloma (MM), sponsored by Peking University People's Hospital. Started Oct 2022; status: recruiting.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05478993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05478993.